explore -WSS

explore

author：entertainment 2025-09-28 06:01:07 Page View：824

Astrazeneca office building -- health policy coverage from STAT — AstraZeneca is suing the Biden administration to stop a new Medicare drug price negotiation program. Adobe

WASHINGTON — AstraZeneca is the sixth drugmaker to pile on a legal challenge to the Biden administration’s drug pricing reform law.

The Medicare drug price negotiation program created in the Inflation Reduction Act is set to kick off in the next week, as officials will release the names of the first 10 medicines that will be selected for the program. Medicines are eligible for selection if they are one of the highest-spend drugs for Medicare, and they have no generic competition.

AstraZeneca makes drugs that could be selected for the list, and asked a Delaware district court judge to rule that Medicare acted illegally and that the law is unconstitutional.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Biogen shutters digital health group, ends Apple study, in cost cutting move
Next article： Supreme Court strikes down use of affirmative action

focus

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

Medicare to cover more brain scans for Alzheimer’s patients

AnewlyapprovedAlzheimer’sdrugmadebyEisaiandBiogen,calledLeqembi,aimstoclearoutamyloidplaquesinpatien

Dobbs anniversary: the lost opportunity of abortion as health care

NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

Group opposing PBM reform sets lobbying record

Aconservativegroupadvocatingagainstchanginghowpharmacymiddlemenoperatespentmorethan$1milliononlobbyi